Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PCVX

Vaxcyte Inc

Dec 08 • 04:00PM ET

46.18

-0.30 -0.65 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX AZN JNJ GSK ALNY NVCR VNDA

| Held by: VTI VB IWM XBI VBK VXF IWN IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.92	Insider Own	3.05%	Shs Outstand	130.03M	Perf Week	1.45%
Market Cap	6.05B	Forward P/E	-	EPS next Y	-6.15	Insider Trans	0.00%	Shs Float	126.92M	Perf Month	10.72%
Enterprise Value	4.42B	PEG	-	EPS next Q	-1.50	Inst Own	107.24%	Short Float	7.36%	Perf Quarter	41.14%
Income	-657.20M	P/S	-	EPS this Y	-42.32%	Inst Trans	-3.91%	Short Ratio	5.43	Perf Half Y	24.14%
Sales	0.00M	P/B	2.08	EPS next Y	-13.75%	ROA	-19.53%	Short Interest	9.34M	Perf YTD	-43.59%
Book/sh	22.25	P/C	3.53	EPS next 5Y	-20.59%	ROE	-20.83%	52W High	94.60 -51.18%	Perf Year	-50.37%
Cash/sh	13.07	P/FCF	-	EPS past 3/5Y	-25.42% -29.88%	ROIC	-22.12%	52W Low	27.66 66.96%	Perf 3Y	1.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.37% 4.73%	Perf 5Y	61.30%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.21%	Oper. Margin	-	ATR (14)	2.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.83	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.75	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	8.83	EPS Q/Q	-87.44%	SMA20	-2.39%	Beta	1.34	Target Price	99.89
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	4.67%	Rel Volume	0.65	Prev Close	46.48
Employees	414	LT Debt/Eq	0.03	Earnings	Nov 04 AMC	SMA200	13.13%	Avg Volume	1.72M	Price	46.18
IPO	Jun 12, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-26.03% -	Trades		Volume	1,142,935	Change	-0.65%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-12-25	Initiated	Goldman	Neutral	$38
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight
Dec-20-24	Initiated	Goldman	Buy	$135
Dec-07-23	Initiated	Mizuho	Buy	$69
Apr-18-23	Initiated	TD Cowen	Outperform
Jan-03-23	Reiterated	Needham	Buy	$52 → $58
Dec-15-22	Initiated	Guggenheim	Buy	$66
Nov-17-22	Initiated	BTIG Research	Buy	$69
Dec-29-21	Resumed	Jefferies	Buy	$50
Jun-24-21	Resumed	Jefferies	Buy	$50
Jul-07-20	Initiated	Needham	Buy	$40
Jul-07-20	Initiated	Cantor Fitzgerald	Overweight	$55
Jul-07-20	Initiated	BofA Securities	Buy	$37

Show Previous Ratings

Dec-08-25 07:00AM	Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults (GlobeNewswire)
Dec-02-25 09:40AM	Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules (Zacks)
Dec-01-25 04:41PM	Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10 (Investor's Business Daily) -8.24%
12:35PM	Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men (MarketWatch)
09:36AM	Moderna Falls as FDA Vows to Impose New Vaccine Requirements (Bloomberg)
09:32AM	Loading…
Nov-18-25 09:32AM	These 3 Stocks Are Using Buybacks to Signal Market Confidence (MarketBeat)
Nov-10-25 08:16PM	TD Cowen Reiterates "Buy" Rating on Vaxcyte (PCVX) With $50 PT (Insider Monkey) +6.38%
Nov-04-25 04:05PM	Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Oct-08-25 12:57AM	Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) (Insider Monkey)
Sep-30-25 02:49PM	What Does Wall Street Think About Vaxcyte (PCVX)? (Insider Monkey)
08:30AM	Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services (GlobeNewswire)
04:12AM	Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study (Insider Monkey)
Sep-12-25 08:55AM	TSCM U.S. Small Cap Growth Strategy Exited Vaxcyte (PCVX) as Its Infant Trial was Less Than Compelling (Insider Monkey)
Sep-03-25 07:30AM	Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose (GlobeNewswire)
Aug-06-25 04:05PM	Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) (GlobeNewswire) -9.06%
11:35AM	Loading…
Jul-31-25 11:35AM	Vaxcyte, Inc. (PCVX)'s VAX-24 Achieves Phase 2 Success in Infants (Insider Monkey)
Jul-16-25 09:38AM	Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX) (Insider Monkey)
Jul-08-25 08:17AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
Jul-02-25 02:47AM	Cantor Fitzgerald Maintains Overweight on Vaxcyte Amid Vaccine Development and ACIP Meeting (Insider Monkey)
May-27-25 09:08AM	Here's Why Vaxcyte (PCVX) Sold Off in Q1 (Insider Monkey)
May-09-25 09:03AM	Is Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back? (Insider Monkey)
May-07-25 04:01PM	Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.45%
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-03-25 05:30AM	Franklin Growth Opportunities SMA Q1 2025 Commentary (Seeking Alpha)
May-01-25 08:00AM	Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors (GlobeNewswire)
Apr-30-25 06:33PM	Hope Amidst The Madness As Market Avoids A New Low (Seeking Alpha)
Apr-29-25 08:24PM	Is Vaxcyte, Inc. (PCVX) the Best Oversold NASDAQ Stock to Buy Right Now? (Insider Monkey) +5.68%
Apr-11-25 04:21PM	Vaxcyte, Inc. (PCVX): Billionaire Stanley Druckenmiller's Top Stock Pick with Huge Upside Potential (Insider Monkey) +11.27%
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -8.96%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
11:00AM	Loading…
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Apr-01-25 12:45PM	Vaxcyte narrow misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI (TipRanks) -14.65%
12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks)
07:23AM	Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr. (Zacks)
07:19AM	Vaxcyte stock sinks despite Phase II IPD vaccine trial success (Clinical Trials Arena)
Mar-31-25 05:20PM	Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (Seeking Alpha) -45.64%
04:12PM	Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies' (Investor's Business Daily)
03:39PM	Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (Seeking Alpha)
09:57AM	Moderna, biotech stocks slide on resignation of FDA official Peter Marks (Yahoo Finance)
09:57AM	Moderna, biotech stocks slide following resignation of FDA official Peter Marks (Yahoo Finance)
09:45AM	Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns (Investor's Business Daily)
07:00AM	Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study (GlobeNewswire)
Mar-30-25 06:30PM	Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now (Insider Monkey)
05:00PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study (GlobeNewswire)
04:08PM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 11:34AM	Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive (Zacks)
09:44AM	Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (InsiderMonkey)
Mar-25-25 08:02AM	Vaxcyte (PCVX) Struggled Amid Political Uncertainty (InsiderMonkey)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Mar-03-25 06:50PM	Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
Feb-26-25 11:03AM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds (Insider Monkey)
07:26AM	Q4 2024 Vaxcyte Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Financial Health and Promising ... (GuruFocus.com)
Feb-25-25 04:01PM	Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
12:30PM	Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts (Insider Monkey)
Feb-13-25 04:14PM	It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care (Investor's Business Daily)
Feb-12-25 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
01:25PM	RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. (Investor's Business Daily)
Feb-08-25 09:22AM	Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-06-25 08:20AM	Vaxcyte advances second stage of Phase 2 study evaluating VAX-31 (TipRanks)
07:22AM	Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants (Clinical Trials Arena)
Feb-05-25 08:00AM	Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Jan-30-25 04:05PM	Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-18-25 05:50PM	Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? (Insider Monkey)
Dec-23-24 10:11AM	Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-09-24 07:57AM	What Makes Vaxcyte (PCVX) An Investment Bet? (Insider Monkey)
Dec-04-24 10:03AM	Vaxcyte doses first subject in pneumococcal conjugate vaccine trial in infants (Clinical Trials Arena)
Dec-03-24 08:00AM	Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants (GlobeNewswire)
Nov-27-24 09:29AM	Vaxcyte (PCVX) Surged On Positive Phase 2 Data For Its Drug (Insider Monkey)
Nov-12-24 07:30AM	Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs (GlobeNewswire)
Nov-06-24 12:09AM	Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight (GuruFocus.com)
Nov-05-24 04:01PM	Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-01-24 09:13AM	Should You Consider Investing in Vaxcyte (PCVX)? (Insider Monkey)
Sep-14-24 07:47PM	Vaxcyte, Inc. (PCVX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-11-24 04:05PM	Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-06-24 04:05PM	Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Obesity drug startup raises $67M; Vors shielded transplant shows promise (BioPharma Dive)
Sep-04-24 11:58PM	Vaxcyte Announces Pricing of $1.3 Billion Public Offering (GlobeNewswire)
Sep-03-24 06:06PM	Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales (Bloomberg) +36.39%
04:09PM	Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market (Investor's Business Daily)
04:01PM	Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
01:22PM	Heard on the Street: Pfizer Better Watch Out for This Biotech (The Wall Street Journal)
11:43AM	Biotech Startup Vaxcyte Is a Threat to Pfizer and Merck. A Vaccine Candidate Is Why. (Barrons.com)
10:48AM	Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data. (Barrons.com)
09:40AM	Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher (Benzinga)
09:07AM	Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market (Investor's Business Daily)
08:10AM	Vaxcytes best-case data for pneumococcal vaccine boost shares (BioPharma Dive)
07:07AM	Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Sep-02-24 06:40PM	Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older (GlobeNewswire)
Aug-06-24 04:05PM	Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 07:02PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
Jul-31-24 09:55AM	Wall Street Analysts See a 25.16% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High? (Zacks)
Jul-29-24 12:00PM	Are You Looking for a Top Momentum Pick? Why Vaxcyte, Inc. (PCVX) is a Great Choice (Zacks)
Jul-02-24 07:01PM	Insider Sale: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX) (GuruFocus.com)
08:30AM	Vaxcyte Appoints John Furey to Board of Directors (GlobeNewswire)
May-10-24 12:32PM	Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview (GuruFocus.com)
May-08-24 10:55PM	PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-04-24 02:31AM	Insider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares (GuruFocus.com)

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lukatch Heath	Director	Apr 08 '25	Option Exercise	16.78	7,000	117,490	14,175	Apr 10 08:06 AM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Apr 07 '25	Option Exercise	20.93	4,777	99,983	131,950	Apr 09 08:05 AM
PICKERING GRANT	CHIEF EXECUTIVE OFFICER	Apr 04 '25	Option Exercise	8.96	20,533	183,888	518,775	Apr 07 07:38 AM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Option Exercise	21.41	5,000	107,050	46,620	Mar 07 04:43 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Mar 05 '25	Sale	70.74	5,000	353,699	41,620	Mar 07 04:43 PM
Eydelman Mikhail	Officer	Mar 05 '25	Proposed Sale	68.87	5,000	344,350		Mar 05 04:10 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Option Exercise	4.38	8,000	35,071	162,931	Mar 03 09:14 PM
Wassil Jim	CHIEF OPERATING OFFICER	Mar 03 '25	Sale	73.27	8,000	586,165	154,931	Mar 03 09:14 PM
Wassil Jim	Officer	Mar 03 '25	Proposed Sale	73.17	8,000	585,360		Mar 03 04:06 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Option Exercise	5.35	8,000	42,800	117,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Feb 18 '25	Sale	83.85	8,000	670,823	109,491	Feb 19 06:04 PM
GUGGENHIME ANDREW	Officer	Feb 18 '25	Proposed Sale	102.08	8,000	816,640		Feb 18 04:29 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 05 '25	Option Exercise	21.41	5,000	107,050	33,222	Feb 07 04:04 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Feb 05 '25	Sale	90.07	5,000	450,369	28,222	Feb 07 04:04 PM
Eydelman Mikhail	Officer	Feb 05 '25	Proposed Sale	87.53	5,000	437,650		Feb 05 04:01 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 03 '25	Option Exercise	2.42	8,000	19,360	213,695	Feb 04 07:20 PM
Wassil Jim	CHIEF OPERATING OFFICER	Feb 03 '25	Sale	86.22	8,000	689,790	205,695	Feb 04 07:20 PM
Wassil Jim	Officer	Feb 03 '25	Proposed Sale	88.20	8,000	705,600		Feb 03 04:05 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 21 '25	Option Exercise	5.35	8,000	42,800	117,491	Jan 22 06:18 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Jan 21 '25	Sale	86.51	8,000	692,101	109,491	Jan 22 06:18 PM
GUGGENHIME ANDREW	Officer	Jan 21 '25	Proposed Sale	86.06	8,000	688,480		Jan 21 04:04 PM
Loxam Teri	Director	Jan 15 '25	Option Exercise	22.70	6,250	141,875	13,425	Jan 17 04:05 PM
Loxam Teri	Director	Jan 15 '25	Sale	85.11	6,250	531,963	7,175	Jan 17 04:05 PM
Loxam Teri	Director	Jan 15 '25	Proposed Sale	80.32	6,250	502,000		Jan 15 04:04 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jan 06 '25	Option Exercise	21.41	5,000	107,050	33,222	Jan 07 04:33 PM
Eydelman Mikhail	SVP, GEN COUNSEL & CORP SEC	Jan 06 '25	Sale	85.58	5,000	427,923	28,222	Jan 07 04:33 PM
Eydelman Mikhail	Officer	Jan 06 '25	Proposed Sale	84.23	5,000	421,150		Jan 06 04:02 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jan 02 '25	Option Exercise	2.42	8,000	19,360	213,695	Jan 03 06:07 PM
Wassil Jim	CHIEF OPERATING OFFICER	Jan 02 '25	Sale	83.66	8,000	669,267	205,695	Jan 03 06:07 PM
Wassil Jim	Officer	Jan 02 '25	Proposed Sale	82.64	8,000	661,120		Jan 02 04:10 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Dec 18 '24	Option Exercise	5.35	8,000	42,800	117,491	Dec 19 04:07 PM
GUGGENHIME ANDREW	PRESIDENT AND CFO	Dec 18 '24	Sale	88.78	8,000	710,249	109,491	Dec 19 04:07 PM
Cowan Elvia	SVP, FINANCE	Dec 16 '24	Option Exercise	25.92	7,716	199,999	19,294	Dec 18 04:13 PM
GUGGENHIME ANDREW	Officer	Dec 18 '24	Proposed Sale	89.83	8,000	718,640		Dec 18 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCVX

Vaxcyte Inc

Upgrade your FINVIZ experience